GT Biopharma stock falls 3.80 percent as financing expands
Published on 09/25/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GT Biopharma stock stood at USD 6.83 on Nasdaq on September 24, 2026 at 4:00 p.m. ET, down 3.80 percent from USD 7.10. The latest financing amendment increased the preferred-stock purchase price to USD 7.75 million, giving the capital structure a fresh investor angle.
Financing reaches USD 7.75 million
According to Stock Titan on September 18, 2026, GT Biopharma amended its Series M 10 percent convertible preferred placement to 8,611.111 shares with an aggregate stated value of USD 8,611,111.11 and a purchase price of USD 7.75 million.
The same filing sets additional greenshoe rights at a stated value of USD 34,675,615 and a purchase price of USD 31,208,054. The comparison is material: the amended initial purchase price exceeds the original USD 7.45 million transaction by USD 300,000, while the stated value rises from USD 8,277,778 to USD 8,611,111.11.
FDA clearance meets funding condition
On September 15, 2026, GT Biopharma announced FDA clearance for a new investigational new drug application for GTB-5550 in multiple myeloma. The planned Phase 1a/1b study would be the first human trial of a B7-H3-targeted TriKE in multiple myeloma and would use subcutaneous administration.
The company said the multiple myeloma trial depends on the timing and receipt of non-dilutive grant funding. Its separate solid-tumor basket trial continues to enroll, with an update anticipated in the fourth quarter of 2026, according to the same September 15 release.
Q2 loss adds financial pressure
GT Biopharma reported a net loss of USD 4.518 million for Q2 2026, compared with a USD 2.833 million loss in Q1 2026, based on the latest quarterly figures reported by Investing.com. Operating loss also widened from USD 2.848 million in Q1 to USD 4.512 million in Q2.
That financial trend places the USD 7.75 million preferred financing beside the clinical update rather than apart from it. The company is advancing a new oncology indication while relying on financing and potential grant support to move the program toward human testing.
Stock stays inside yearly range
GT Biopharma stock traded between USD 6.59 and USD 7.10 during the September 24 session. Its 52-week range was USD 4.91 to USD 34.25, while market capitalization stood at USD 8,620,525 and volume reached 28,114 shares on that date.
The daily decline of 3.80 percent leaves the shares 38.80 percent above the 52-week low and 80.06 percent below the 52-week high. For investors, the financing terms and the grant-dependent clinical timetable are the clearest numbers shaping the next phase of the story.
GT Biopharma stock data
- Company: GT Biopharma, Inc.
- Ticker: GTBP
- Trading venue: Nasdaq
- Price (as of September 24, 2026, 4:00 p.m. ET): USD 6.83
- Market capitalization: USD 8,620,525 (as of September 24, 2026)
- 52-week range: USD 4.91 to USD 34.25 (as of September 24, 2026)
- Sector / Industry: Healthcare / Biotechnology
